1402888-95-2

Upstream product

• 2550-36-9 Cyclohexylmethyl bromide 
• 3284-51-3 ethyl 5-methyl-1H-pyrrole-2-carboxylate 
• 129316-09-2 1,3-dibromo-5-t-butylbenzene 
• 4897-84-1 Methyl 4-bromobutyrate 
• 1402888-94-1 5-(3-(tert-Butyl)-5-hydroxyphenyl)-1-(cyclohexylmethyl)-2-methyl-1H-pyrrole-3-sulfonamide 
• 1402889-83-1 Ethyl 1-(cyclohexylmethyl)-5-methyl-1H-pyrrole-2-carboxylate 
• 1402889-84-2 Ethyl 1-(cyclohexylmethyl)-5-methyl-4-sulfamoyl-1H-pyrrole-2-carboxylate 
• 1402889-85-3 1-(Cyclohexylmethyl)-2-methyl-1H-pyrrole-3-sulfonamide 
• 1402889-86-4 5-Bromo-1-(cyclohexylmethyl)-2-methyl-1H-pyrrole-3-sulfonamide 
• 1047661-27-7 1-bromo-3-(tert-butyl)-5-methoxybenzene 
• 889654-05-1 2-(3-(tert-Butyl)-5-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1402890-07-6 3-tert-butyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol 

Downstream Products

• 1402888-96-3 4-(3-(tert-Butyl)-5-(1-(cyclohexylmethyl)-5-methyl-4-sulfamoyl-1H-pyrrol-2-yl)phenoxy)butanoic acid 

Relevant academic research and scientific papers

Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases

The invention provides modulators for the orphan nuclear receptor RORγ and methods for treating RORγ mediated diseases by administrating these novel RORγ modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.